Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications.
Yueying LiShu-Yuan XiaoPublished in: Journal of medical virology (2020)
During the clinical course of coronavirus disease 2019 (COVID-19), it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. Mild increase in sinusoidal lymphocytic infiltration, sinusoidal dilatation, steatosis and multifocal hepatic necrosis are the pathologic changes reported. Direct viral-induced cellular injuries and potential hepatotoxicity from therapeutic drugs are two likely underlying mechanisms. In addition, the pre-existing chronic liver disease exacerbated during COVID-19, and COVID-19-related hyperinflammatory reactions may contribute to liver injury as well. Further studies of additional autopsy cases will help clarifying these possibilities.
Keyphrases
- drug induced
- liver injury
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- neoadjuvant chemotherapy
- oxidative stress
- radiation therapy
- squamous cell carcinoma
- climate change
- metabolic syndrome
- diabetic rats
- early onset
- high glucose
- risk assessment
- human health